* Cypros Pharmaceutical Corp., of Carlsbad, Calif.(NASDAQ:CYPR), initiated a special exercise program for thoseholding Redeemable Class A warrants on Nov. 8. They can exercisethem until Dec. 9 and receive one-half of a Class B warrant and1.175 shares of common stock upon payment of about $9.25 perClass A warrant exercised.
* Advanced Tissues Sciences Inc., of La Jolla, Calif., received FDAapproval for a supplement to its investigational device exemption tobegin a pivotal trial of Dermagraft-Transitional Covering in severelyburned patients.
* Alamar Biosciences Inc., of Sacramento, Calif., an in vitrodiagnostics testing company, completed a private financing thatraised $2.5 million, more than it initially was seeking.
* Avid Therapeutics Inc., of Philadelphia, secured rights to a novelclass of compounds, called polyoxometalates, to treat respiratorysynctial virus and influenza.
* DNA Plant Technology Corp., of Oakland, Calif., announced ajoint marketing agreement between its wholly owned producesubsidiary, FreshWorld, and Fresh Choice Produce Inc., a privatevegetable grower and shipper in Salinas, Calif.
* GeneMedicine Inc., of Houston, said Mark Germain resigned fromhis position as director and chairman of the company's board ofdirectors.
* ICN Pharmaceuticals Inc., of Costa Mesa, Calif., said it acquiredthe rights to develop and commercialize a group of compoundsrelated to and including human growth hormone releasing factor orthe U.S. and other markets from Fujisawa USA Inc., of Japan.
* IMRE Corp. and Virginia Mason Medical Center, both of Seattle,said that CELx Corp., IMRE's diagnostic subsidiary, obtained anexclusive worldwide license with the Virginia Mason ResearchCenter for its rheumatoid arthritis genetic test and associated U.S.patent.
* NeoRx Corp., of Seattle, announced an agreement with CordisCorp., of Miami, in which Cordis will supply its Micro-InfusionCatheter for use with NeoRx's Biostent anti-restenosis product,currently under development.
* North American Vaccine, of Beltsville, Md., said results of itsPhase III trial of its diphtheria-tetanus-acellular pertussis vaccine willbe unblinded this week and released later this month by the NationalInstitute of Child Health and Human Development of the NationalInstitutes of Health.
* T Cell Sciences Inc., of Needham, Mass., adopted a shareholderrights plan that it said is not in response to any specific takeoverthreat or proposal.
* Viagene Inc., of San Diego, said an interim evaluation of itsdirectly injected gene therapy product for HIV infection supported aproduct-related enhancement of HIV-specific cytotoxic Tlymphocyte activity in HIV-infected patients.
(c) 1997 American Health Consultants. All rights reserved.